THE UNIVERSITY OF KENTUCKY joined the TriNetX network for its clinical trial design and clinical research. Pharmaceutical researchers will gain access to the university’s clinical data through TriNetX’s network of healthcare institutions representing over 37 million patients in the U.S. and Europe to support clinical study and protocol design, site selection, and patient recruitment across...
FDA has been taking a look at psychedelics as a potential treatment for psychiatric and substance abuse disorders, recently publishing a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA.
